Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-FC705
- Development stage
- Unknown
- Lead developer
- FutureChem
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-FC705 is a PSMA-targeted radiopharmaceutical developed by FutureChem Pharma for the treatment of prostate cancer. It consists of a small-molecule ligand that binds with high affinity to the prostate-specific membrane antigen (PSMA), which is overexpressed on the surface of most prostate cancer cells. The ligand is conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu). Upon binding to PSMA-expressing cells, the compound is internalized, allowing the 177Lu to deliver localized ionizing radiation, leading to DNA damage and cell death in the tumor while minimizing exposure to healthy tissues. As of 2024, it is in Phase 3 clinical development in South Korea for metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- Lutetium (177Lu) FC705177Lu-labeled FC705
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-FC705.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-FC705.